The New Perimeter Problem
The biotech industry was built on collaboration. Yet the very networks designed to connect researchers, clinical partners, and global offices are now struggling to keep pace with that mission.
Most firms still rely on traditional VPNs and secure-access gateways built for a different era, one where users logged in from a single office, not from labs, homes, and mobile devices scattered around the world.
Today, poor VPN performance isn’t just a nuisance. It’s a security, compliance, and operational risk.
At Single Point of Contact, we’ve observed a growing trend: biotech firms losing visibility and control as data moves beyond the traditional network edge. The fix isn’t another patch or appliance, it’s a shift toward modern, identity-driven access.
- Why Legacy VPNs Are Struggling to Keep Up
Traditional VPN and secure-gateway architectures were never meant to handle the distributed, data-intensive workflows of modern biotech.
Core weaknesses include:
- Bottlenecked throughput: Legacy concentrators can’t handle concurrent research-grade traffic such as genomic uploads or AI/ML pipelines.
- Centralized choke points: All traffic, even to cloud apps, is routed through a single hub, creating latency and poor user experience.
- Limited context awareness: VPNs trust devices once authenticated, offering little insight into user behavior or session risk.
- Static access policies: Outdated rules make it difficult to adapt to changing compliance requirements or partner access needs.
- Complex certificate management: Renewals, device provisioning, and endpoint hygiene enforcement consume time and increase errors.
For biotech firms, these limitations create more than just IT headaches, they introduce systemic security and compliance vulnerabilities.
- The Security and Compliance Implications
When VPN and secure-gateway performance degrades, scientists and partners look for workarounds.
They share data over unapproved channels, upload sensitive files via personal devices, or temporarily disable security features to complete urgent work.
Each workaround chips away at compliance controls and introduces potential regulatory violations.
Risks amplified by poor VPN performance:
- HIPAA exposure: Inconsistent encryption and unsecured data transfers jeopardize protected health information (PHI).
- FDA 21 CFR Part 11 violations: Lack of access audit trails or inconsistent authentication records undermines data integrity requirements.
- Vendor access gaps: Contract researchers and partners often reuse generic credentials or unmanaged endpoints.
- Shadow IT proliferation: Users bypass VPNs for speed, adopting unauthorized cloud storage or messaging apps.
- Unmonitored data flow: Without centralized telemetry, anomalous access or exfiltration attempts go unnoticed.
The regulatory consequences are severe, from costly breach notifications to reputational damage that can delay clinical trials or partnerships.
III. Why Traditional Fixes Don’t Work Anymore
Many biotech firms attempt to “tune” existing VPNs with hardware upgrades or bandwidth increases. But these efforts treat symptoms, not causes.
The real issue is architectural misalignment:
- VPNs were designed for point-to-point connectivity, not multi-cloud ecosystems.
- Secure-access gateways often sit behind overloaded firewalls, slowing authentication and inspection.
- Every new collaborator or endpoint increases administrative burden exponentially.
The more a biotech company scales, the worse the performance gets. What’s needed is a model built around identity, context, and continuous verification, not static network tunnels.
- How to Modernize Remote Access Securely
Modernization doesn’t mean abandoning security; it means re-architecting it.
Below are modernization paths that leading biotech firms are adopting to replace or augment legacy VPN and gateway models.
- Adopt a Zero-Trust Network Access (ZTNA) Framework
- Replace “trust but verify” with “never trust, always verify.”
- Grant access based on user identity, device health, and contextual risk, not just IP addresses.
- Apply continuous monitoring throughout the session, not just at login.
- Segment access by application, not entire network zones, reducing lateral-movement risk.
- Integrate Identity-Centric Access Controls
- Centralize identity management with SSO, MFA, and adaptive authentication.
- Enforce least-privilege principles across both employees and external partners.
- Tie every access event to a verifiable identity for compliance auditing.
- Migrate Toward Secure Access Service Edge (SASE)
- Combine network security and connectivity into a unified cloud-based model.
- Route users directly to the applications they need, improving latency and reducing backhaul traffic.
- Embed security inspection, threat prevention, and DLP at the edge, not after the fact.
- Strengthen Endpoint and Device Security
- Require posture checks before granting access (OS version, encryption status, EDR presence).
- Implement continuous endpoint visibility through managed detection and response (MDR).
- Enforce automated quarantine for compromised or non-compliant devices.
- Redesign Remote Collaboration Security
- Use secure file-exchange portals integrated with audit logging.
- Apply conditional access to third-party researchers based on contractual scope.
- Implement data-loss prevention rules that prevent unauthorized exports of clinical or genomic data.
- Measuring the ROI of Secure-Access Modernization
C-suite leaders often ask: Is this investment operational or strategic?
The answer is both. Modern secure-access architecture delivers measurable returns:
- Improved uptime: Eliminates single-point bottlenecks that stall research workflows.
- Reduced compliance exposure: Built-in logging and continuous authentication simplify audits.
- Lower support costs: Fewer help-desk tickets related to access failure or credential resets.
- Stronger partner trust: Controlled access reassures vendors and investors handling sensitive IP.
- Scalable performance: Dynamic routing and edge enforcement accommodate growth without re-architecture.
Modernization isn’t just an IT upgrade, it’s a business-continuity strategy.
- Implementation Considerations for Biotech Executives
To modernize safely, executives should require their IT and security teams to:
- Conduct a comprehensive access audit identifying every VPN user, device, and external collaborator.
- Classify applications and data by sensitivity to determine appropriate access models.
- Pilot ZTNA or SASE solutions in low-risk departments before full rollout.
- Review compliance mappings (HIPAA, GDPR, 21 CFR Part 11) for access and identity control alignment.
- Engage a trusted MSSP to monitor and manage performance, security, and configuration drift.
The transformation requires both expertise and continuous oversight, a challenge that internal teams alone often cannot sustain.
VII. The Role of a Strategic Managed Security Partner
Modern access control is not a one-time project. It’s an evolving framework that adapts as threats, regulations, and user behaviors change.
An experienced partner like Single Point of Contact can help biotech organizations:
- Architect and deploy zero-trust access models across hybrid environments.
- Monitor and tune VPN and SASE performance 24×7 through their Security Operations Center (SOC).
- Integrate endpoint, identity, and DLP controls for unified visibility.
- Provide compliance reporting and breach-response readiness aligned to HIPAA and FDA expectations.
Their role is to simplify complexity, giving your IT and research leaders the freedom to innovate securely.
Conclusion: Rebuilding Trust in Remote Access
In biotech, connectivity fuels discovery. But as operations expand, the legacy VPN model can’t keep up with the pace or precision the industry demands. Unstable access is more than an inconvenience, it’s a blind spot that weakens compliance, threatens IP, and frustrates innovation.
By modernizing remote access around identity, context, and zero-trust principles, biotech leaders can achieve both security and speed. And with Single Point of Contact as a managed security ally, that modernization can happen strategically without disrupting the science driving your mission forward.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
